CVL-231

DRUG3 trials

Sponsors

Cerevel Therapeutics, LLC

Conditions

Blood PressureSchizophrenia

Phase 1

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

CompletedNCT04136873

Cerevel Therapeutics, LLCSchizophrenia

Start: 2019-10-15End: 2021-06-03Updated: 2021-07-02

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

CompletedNCT04787302

Cerevel Therapeutics, LLCSchizophrenia

Start: 2021-06-01End: 2023-07-14Updated: 2023-07-27

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

CompletedNCT05245539

Cerevel Therapeutics, LLCBlood Pressure, Schizophrenia

Start: 2022-01-24End: 2022-11-14Updated: 2022-12-14

Related Papers

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.

2022-12-0187 citations